{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001023","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.106583+00:00","generated_at":"2026-06-20T11:50:49.129235+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Prelude Therapeutics amends bylaws for universal proxy rules and DGCL updates","bullets":["Amended bylaws effective Jan 19, 2023, addressing SEC universal proxy rules (Rule 14a-19) and recent DGCL amendments.","Revised advance notice provisions require additional disclosures, limit nominees to board seats available, and mandate nominee interviews.","New rule requiring universal proxy solicitors to use non-white proxy cards; stockholders must certify compliance with Rule 14a-19.","Added emergency bylaw provision for board/quorum during crises; updated electronic notice procedures.","Updates to stockholder meeting conduct, including attendance procedures and Rule 14a-8 proponent rules."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001023","json":"https://secwatch.observer/filing/0000950170-23-001023.json","markdown":"https://secwatch.observer/filing/0000950170-23-001023.md","text":"https://secwatch.observer/filing/0000950170-23-001023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/0000950170-23-001023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/prld-20230119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:50:49.129235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"087d4e4bdbae0eaf47044636c4777088c33d35d3","claim":"Prelude Therapeutics Inc: Adopted amended and restated bylaws to implement changes related to universal proxy rules, recent DGCL amendments, and other procedural and administrative updates, effective January 19, 2023 (effective 2023-01-19).","evidence_excerpt":"On January 19, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Prelude Therapeutics Incorporated (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/0000950170-23-001023-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-01-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}